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Introduction. Community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) infections 
are found with increasing the frequency, both in healthy individuals in the community and in hospitalized 
patients. In Colombia and the Andean region, CA-MRSA isolates have a genetic background that is 
related to the pandemic USA300 clone.
Objective. Two molecular methods are designed and standardized for the rapid differentiation of 
Colombian community-acquired and hospital-acquired methicillin-resistant Staphylococcus aureus 
(HA-MRSA) isolates.
Materials and methods. Two molecular methods were standardized for the identification of CA-MRSA 
isolates. The first method was based on the differential digestion of the carbamate kinase (arcC) and 
guanylate kinase (gmk) genes in the sequences type 5 (ST5) in the HA-MRSA isolates and 8 (ST8) in 
the CA-MRSA isolates. The second method was based on the PCR amplification of 5 specific virulence 
factors found in CA-MRSA and HA-MRSA isolates. The specificity and precision of each method were 
evaluated using 237 clinical MRSA isolates.
Results. The first method identified 100% and 93.2% of the CA-MRSA and HA-MRSA isolates, 
respectively. The second method also correctly identified the two isolates types (CA-MRSA and HA-
MRSA).
Conclusions. These two methods are a convenient alternative for the rapid identification of the CA-
MRSA isolates, compared with other techniques such as pulsed field gel electrophoresis and multilocus 
sequence typing, which are time-consuming and more expensive.
Key words: Methicillin-resistant Staphylococcus aureus, community-acquired infections, bacterial 
typing techniques, multilocus sequence typing, enterotoxins.
Diseño de dos metodologías moleculares para la rápida identificación de aislamientos de 
Staphylococcus aureus resistente a meticilina asociados a la comunidad en Colombia
Introducción. Los aislamientos de Staphylococcus aureus resistente a la meticilina asociado a la 
comunidad (SARM-AC), están aumentando la frecuencia de infecciones en personas sanas de la 
comunidad y en pacientes hospitalizados. En Colombia y en la región andina estos aislamientos tienen 
un componente genético relacionado con el clon pandémico USA300.
Objetivo. Diseñar y estandarizar dos metodologías para la diferenciación rápida de aislamientos 
colombianos de S. aureus resistente a la meticilina asociado a la comunidad de los asociados al 
hospital (SARM-AH).
Materiales y métodos. Se estandarizaron dos metodologías moleculares para la identificación de 
aislamientos de S. aureus resistente a la meticilina asociado a la comunidad. La primera se basa en la 
digestión diferencial con tres enzimas de restricción de los genes cinasa de carbamato (arcC) y cinasa 
de guanilato (gmk) para los tipos de secuencia 5 (ST5) y 8 (ST8), correspondientes a aislamientos de 
S. aureus resistente a la meticilina asociado al hospital y asociado a la comunidad, respectivamente. 
La segunda se basa en la amplificación por reacción en cadena de la polimerasa de cinco factores 
de virulencia que se encuentran de manera diferencial en estos aislamientos. Las dos metodologías 
fueron validadas en 237 aislamientos clínicos de S. aureus resistente a la meticilina.
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Resultados. Con la primera metodología se identificaron el 100 % y 93,2 % de los aislamientos de S. 
aureus resistente a la meticilina asociado a la comunidad y asociado al hospital, respectivamente. Con 
la segunda metodología se identificaron correctamente los dos tipos de aislamientos. 
Conclusiones. Estas dos metodologías son una buena alternativa en términos de ahorro en tiempo 
y dinero comparadas con otras técnicas, como la electroforesis en campo pulsado y la tipificación 
de secuencias multilocus para la rápida identificación de aislamientos de S. aureus resistente a la 
meticilina asociado a la comunidad en Colombia.
Palabras clave: Staphylococcus aureus resistente a meticilina, infecciones comunitarias adquiridas, 
técnicas de tipificación bacteriana, tipificación de secuencias multilocus, sequence typing, 
enterotoxinas.
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The first infections due to community-acquired 
methicillin-resistant Staphylococcus aureus (CA-
MRSA) were reported in Australia in 1990 (1). Since 
then the number of reported cases has increased 
around the world, demonstrating a high capacity 
for infection and dissemination (2). In addition, 
the CA-MRSA isolates have begun to cause 
infections in hospitalized patients and to replace 
the clones of hospital-acquired methicillin-resistant 
Staphylococcus aureus (HA-MRSA) (3,4). These 
isolates differ from the HA-MRSA forms in that they 
are more virulent and possess genetic components 
that cause infections even in healthy persons 
without apparent risk factors or prior contact in 
a hospital environment (2,5,6). Even though HA-
MRSA has been a clinical concern for a long time, 
the infections caused by CA-MRSA have become 
the focal point for clinical and researchconcern.
Methicillin-resistant Staphylococcus aureus (MRSA) 
presents a conserved clonal structure with a 
reduced number of clones that have the capacity 
for global dissemination. Five CA-MRSA pandemic 
clones that have been described based on their 
sequence type (ST), as determined by multilocus 
sequence typing (MLST): European clone (ST80); 
Oceanic clone (ST30); North-West Pacific clone 
(ST59); USA300 (ST8) and USA400 (ST1) (2). In 
South America, the appearance and dissemination 
of at least three of the CA-MRSA clones have been 
reported, but with different genetic characteristics. 
In Brazil and Uruguay the most prevalent CA-MRSA 
clone possesses a type of staphylococcal cassette 
chromosome mec (SCCmec) IVc, the Panton-
Valentine leukocidin (PVL) toxin and ST30. These 
are genetically related to the CA-MRSA clone in 
Australia and Oceania. In Argentina, a CA-MRSA 
clone has been reported with a SCCmec IVa, 
positive PVL, ST5 and with no apparent genetic 
relation to one of the CA-MRSA pandemic clones 
(7,8). In contrast, the CA-MRSA clone that circulates 
in the Andean region (Colombia, Ecuador, Peru 
and Venezuela) is related to the USA300 clone, 
possesses an ST8, a spa type t008, has PVL and a 
SCCmec IVc (9,10).
In Colombia, two predominant HA-MRSA clones 
have been found--the Chilean/Cordobés and the 
Pediatric clones. The first has SCCmec type I and 
the second has a SCCmec type IV. These clones 
do not possess the LukF-PV/LukS-PV genes, and 
both have an ST5 (allele combination 1, 4, 1, 4, 
12, 1, 10) and belong to the clonal complex 5. In 
contrast, the Colombian CA-MRSA isolates are 
related to the USA300 clone and have an ST8 
(allele combination 3, 3, 1, 1, 4, 4, 3).
In microbiological terms, CA-MRSA and HA-MRSA 
isolates are very difficult to differentiate. Techniques 
such as pulsed field gel electrophoresis (PFGE) and 
multilocus sequence typing (MLST) must be used. 
PFGE is based on the digestion of the chromosomal 
bacterial DNA with a restriction enzyme (SmaI 
in the case of S. aureus). The DNA fragments 
obtained are separated by PFGE, generating a 
banding pattern (pulsotype) (11). The second 
method, MLST,  identifies the allelic variation, at 
the sequence level, of 7 standard housekeeping 
genes chosen for S. aureus--carbamate kinase 
(arcC), shikimate kinase (aroE), glycerol kinase 
(glpF), guanylate kinase (gmk), phosphate 
acetyltransferase (pta), triosephosphate isomerase 
(tpi) and acetyl coenzyme A acetyltransferase 
(yqiL).  Each combination of the 7 alleles provides 
a specific sequence type in accordance with 
the MLST database (available at www.mlst.
net). Isolates with related STs determine a clonal 
complex (CC). The use of these techniques has 
allowed the differentiation of the pandemic MRSA 
clones (12-15).
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PFGE and MLST are expensive techniques that 
are time-consuming and require a staff trained in 
the use of specialized facilities and equipment. 
Additionally, analysis of results and the comparison 
of the pulsotypes are not straightforward tasks. For 
these reasons, the development of methods has 
become important to allow the rapid identification of 
CA-MRSA isolates and provide improved treatment 
of the infections caused by these microorganisms.
Therefore, the objective was to design and 
standardize two methods for the rapid identification 
of Colombian CA-MRSA isolates related to the 
USA300 clone.
Materials and methods
Staphylococcus aureus isolates
The MRSA clinical isolates were derived from 
strains banked at the Bacterial Molecular Genetic 
Laboratory of the Universidad El Bosque in Bogotá, 
Colombia. The reference strains used were as 
follows: USA300-0114 (ST8-MRSA-IVa), CHL93, 
corresponding to the Chilean/Cordóbes clone (ST5-
MRSA-I),  and HDE3, corresponding to the Pediatric 
clone (ST5-MRSA-IV). Two hundred and thirty seven 
MRSA clinical isolates were analyzed--197 isolates 
(153 CA-MRSA and 44 HA-MRSA) were previously 
classified as CA-MRSA and HA-MRSA. Genetic 
relationships established in circulating clones by 
means of PFGE and MLST and microbiological 
factors such as minimal inhibitory concentration (MIC) 
for oxacillin, gentamicin, clindamycin, erythromycin, 
ciprofloxacin, tetracycline, chloramphenicol, rifampi-
cin, trimethoprim-sulfamethoxazole, vancomycin 
and linezolid. In addition, 40 MRSA isolates were 
first classified as CA-MRSA and HA-MRSA using 
the two methodologies standardized, and then the 
isolates were confirmed by molecular and genetic 
characterization.
DNA extraction
The isolates were recovered in brain-heart infusion 
broth (BHI) after incubation for 24 hours at 37°C 
under aerobic conditions. The DNA was extracted 
by resuspension of the colony in 30 µL of distilled 
and deionized water and later boiled at 94°C for 10 
min. Finally, it was centrifuged at 5,000 rpm for five 
min and 5 µL of supernatant solution was used as 
the DNA template for each reaction. 
Determination of the allelic variations and the 
search for specific restriction enzymes
The sequences for the alleles of the genes arcC, 
aroE, glpF, gmk, pta, tpi and yqiL for ST5 and ST8 
were taken from the MLST website at www.mlst.net. 
The nucleotide variations for each of the genes and 
the search for differentiating restriction enzymes 
were determined by means of the Restriction of 
DNA program (16). These results were confirmed 
by means of multiple alignment of each allelic 
pair using the Multalin program, available at 
www.expasy.org. The cutting sites for the chosen 
restriction enzymes were confirmed through the 
programs NEBcutter (17) and Webcutter, available 
at http://rna.lundberg.gu.se/cutter2/.
Amplification of the genes arcC (carbamate 
kinase) and gmk (guanylate kinase) and cutting 
with restriction enzymes
The design of the primers was made using the total 
sequence of each gene, downloaded as part of the 
genome of the USA300 strain that was available in 
GenBank (access number gi87159884) and using 
the programs PRIMER and PRIMER3 (18,19). The 
parameters used for the design of the primers were 
as follows: (1) the size of the product to amplify, (2) 
size of the products generated after the restriction 
(easy identification of the alleles), (3) number of 
additional cuts of each restriction enzyme inside the 
amplified product, (4) a GC percentage between 
40-60%, (5) a maximum variation of 5°C in their 
annealing temperatures, and (6) a lack of formation 
of secondary structures. The optimal concentrations 
of MgCl2, dNTPs, primers and DNA were determined, 
as were the best thermal conditions, by a trial and 
error approach. The amplified products of each 
gene were digested with the selected restriction 
enzymes at 37°C for 2 hours. Finally, the restriction 
patterns were visualized in 1.5% agarose gels dyed 
with ethidium bromide.
Multiple amplification of the genes sek, bsaB, 
lukF-PV/lukS-PV, sem and seo
A multiple PCR was standardized for the simultaneous 
amplification of the genes sek, bsaB, lukF-PV/lukS-
PV, sem and seo that codify for the enterotoxin K, 
bacteriocin B, PVL, enterotoxin M and enterotoxin O, 
respectively. The primers used for the amplification 
of these genes are shown in table 1.
Results
First Method: Differential digestion of the 
carbamate kinase (arcC) and guanylate kinase 
(gmk) genes in the sequences type 5 (ST5) and 
8 (ST8)
The sequence types ST5 and ST8 have different 
alleles in 6 of the 7 genes used for the MLST (arcC, 
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aroE, gmk, pta, tpi and yqiL). The allele 1 of the 
gene glpF is the same for these two types of ST. 
The nucleotide variations of each allelic pair were 
determined for each of the 6 genes in the two ST 
types by means of multiple alignments. In total, 17 
variations were found--3 in the arcC gene, 2 in the 
aroE gene, 5 in the gmk gene, 1 in the pta gene, 2 
in the tpi gene and 4 in the yqiL gene (table 2). For 
each allelic pair, sequences of 23 nucleotides were 
taken that included each variation (10 nucleotides 
on each side of the variation); then the differential 
cutting restriction enzymes were selected by means 
of the “Restriction of DNA”, Webcutter 2.0 and 
NEBcutter V2.0 programs. Appropriate restriction 
enzymes found were for only some variations of 
the arcC and gmk genes. For the arcC gene, the 
HinfI enzyme (GANTC cutting and recognition 
sequence) cut allele 1 of ST5 in the position 198, 
but it did not cut allele 3 of ST8 for the nucleotide 
variation C198T. For the gmk gene, two restriction 
enzymes cut differently in three of the five variants. 
The HhaI enzyme (GCGC cutting and recognition 
sequence) cut only allele 1 for ST8 in the position 
286 but it did not cut allele 4 of ST5 for the 
nucleotide variation T286C. The CaiI enzyme (with 
CAGNNNCTG recognition sequence) cut allele 1 
of ST8 but not allele 4 of ST5 for the consecutive 
variations C357T and A358G (table 2). 
The arcC gene has a total size of 942 bp; the 
designed primers amplify an expected product of 
332 bp and include the variation C198T. The gmk 
gene has total size of 624 bp.  For the primer design, 
the amplified product was expected to include all 
of the 3 variants, T286C, C357T and A358G. The 
expected size was 557 bp (table 1).
After a standardization process, the optimal concen-
trations of the reagents for the amplification of 
the arcC and gmk genes were as follows: 2.5 
mM of MgCl2, 200 µM of dNTPs, 200 nM of each 
primer (forward and reverse) and 2 units of Taq 
Polymerase. The two genes were amplified using 
the same temperature profile, which consisted of: 
an initial cycle of 94°C for 5 min, followed by 30 
cycles of 94°C for 30 sec, 50°C for 30 sec and 
72°C for 1 min; and a final extension cycle of 72°C 
for 7 min in a final volume of 20 µL. Later, 10 µL 
of the PCR product, without previous purification, 
was incubated at 37°C with each of the respective 
restriction enzymes for 2 hours. For the restriction 
of the arcC gene, 7 units of the HinfI enzyme were 
used, and the fragments expected in accordance 
with the ST were as follows: 332 bp for an isolate 
with allele 3 (ST8), the amplified product size (uncut 
by the restriction enzyme), and two products of 245 
bp and 87 bp for allele 1 (ST5) (figure 1). For the 
restriction of the gmk gene, 5 units of the CaiI or 
HhaI enzymes were used. The expected fragments 
with the CaiI enzyme were 557 bp for the allele 4 
(ST5), uncut PCR product, and two products of 390 
bp and 167 bp for allele 1 (ST8). In the case of the 
HhaI enzyme, this cuts the two alleles of the gmk 
gene, but produces a different number of fragments-
-for allele 4 of ST5 it cuts once and produces two 
fragments of 429 bp and 124 bp;, for allele 1 of ST8 
it cuts twice and produces three fragments of 323 
bp, 124 bp and 105 bp (figure 1).
The restriction of the arcC gene with the HinfI 
enzyme in the Chilean clone (ST5) produced 
two fragments of 245 bp and 87 bp. In the case 
of the USA300 clone (ST8), a fragment of 332 bp 
was obtained that corresponded to the size of the 
amplified product, i.e., no cutting occurred with this 
enzyme. The restriction of the gmk gene with the 
CaiI enzyme in the USA300 clone (ST8) produced 
two fragments of 340 bp and 112 bp. For the Chilean 
clone (ST5) a fragment of 557 bp was obtained, 
indicating no activity of the restriction enzyme. The 
restriction of the gmk gene with the HhaI enzyme 
in the Chilean clone (ST5) produced two fragments 
of 428 bp and 129 bp, and for the USA300 clone 
(ST8) three fragments of 323 bp, 129 bp and 105 
bp (figure 1). The results obtained for the Pediatric 
clone HDE3 (ST5) were the same as those found 
for the Chilean clone.
From these results, the following deductions were 
made. (1) The HinfI enzyme cut allele 1 of the arcC 
gene in the ST5 isolates, but it did not cut allele 3 
of the ST8 isolates. (2) The CaiI enzyme cut allele 
1 of the gmk gene present in the ST8 isolates, but 
it did not cut allele 4 of ST5 isolates. (3) In the case 
of the HhaI enzyme, it cut the two alleles of the gmk 
gene, but with a different frequency and generated 
fragments with different sizes. (4) Allele 1, present 
in the isolates with ST8, was cut at two sites and 
generated three products. (5) For allele 4, present 
in ST5 isolates, HhaI cut in only one site and 
generated two products, one with a greater size 
(428 bp) than that expected for allele 1 (323 bp). 
Second method: PCR amplification of the 5 
specific virulence factors
Chavarro et al. (2009) carried out a study on the 
frequency of 24 virulence factors in 270 Colombian 
MRSA isolates (86 CA-MRSA isolates and 184 
HA-MRSA isolates) (9). The sek, seq and lukF-
PV/lukS-PV genes were found only in CA-MRSA 
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isolates with a frequency of 80%, 82% and 92%, 
respectively.  The seg, sei, sem, sen and seo genes, 
that make up the enterotoxin genomic cluster (egc) 
were found only in the HA-MRSA isolates with a 
frequency of 85%. Recently Álvarez et al. analyzed 
153 MRSA isolates recovered from pediatric 
infections and found the sek, seq and lukF-PV/
lukS-PV genes only in the CA-MRSA isolates, with 
frequencies of 71%, 71% and 100%, respectively. 
The egc genes were found in all of the HA-MRSA 
isolates. In addition, they found that 90% of the CA-
MRSA isolates had the bsaB gene that codifies for 
a bacteriocin, whereas this gene was not found in 
the HA-MRSA isolates (unpublished data).
Using these results, primers were specifically 
designed for the simultaneous amplification of the 
lukF-PV/lukS-PV, sek, bsaB, sem and seo genes. 
The first three genes act as specific genetic markers 
for Colombian CA-MRSA isolates and the remaining 
two for Colombian HA-MRSA isolates (figure 2). 
The primer sequences and the size of the expected 
amplification products are detailed in table 1. 
The optimal concentrations of the reagents found for 
the simultaneous amplification of the 5 genes were 
as follows: 2.5 mM of MgCl2, 200 µM of dNTPs, 200 
nM of each primer and 1 unit of Taq polymerase. 
The optimal profile of temperatures was: an initial 
95°C for 5 min, followed by 30 cycles of 95°C for 45 
sec, then 54°C for 45 sec and 72°C for 2 min, with a 
final extension of 72°C for 7 min (figure 2).
Validation of the two methods
The methods were validated evaluating 197 and 
40 MRSA clinical isolates, with and without micro-
biological, genetic and molecular characterization, 
respectively. Among the 197 MRSA isolates 
previously characterized, 153 (77.6%) were 
classified as CA-MRSA and 44 (22.3%) were 
classified as HA-MRSA. With the first method, 
the 153 CA-MRSA isolates evaluated showed a 
restriction profile of the genes arcC and gmk expected 
of CA-MRSA isolates, while of the 44 HA-MRSA 
isolates analyzed, 41 showed restriction profiles 
that were characteristic of HA-MRSA isolates and 
3 (6.8%) isolates presented profiles with restriction 
characteristics of CA-MRSA isolates for the HinfI 
and CaiI enzymes. However, the amplified fragment 
of the gmk gene was not cut by the HhaI enzyme 
in those three isolates, an unexpected result for the 
ST5 and ST8 isolates. This suggests the possibility 
that these 3 isolates possess a different allele of 
the gene gmk. To confirm this hypothesis, the allele 
of this gene will be sequenced for these samples. 
These results show that the first standardized 
method had a high specificity (98.5%) and correctly 
identified all of the CA-MRSA isolates. The second 
method correctly identified both the CA-MRSA and 
HA-MRSA isolates (table 3). The 153 CA-MRSA 
isolates amplified at least one of the three genes 
(sek, bsaB or lukF-PV/lukS-PV). One hundred 
thirteen (73.8%) isolates amplified the three genes, 
29 (18.9%) only amplified the lukF-PV/lukS-PV 
gene, 8 (5.2%) amplified the sek and bsaB genes 
and 3 (2.0%) isolates amplified the lukF-PV/lukS-
PV and bsaB genes. All of the HA-MRSA isolates 
amplified the sem and seo genes. 
Among the 40 MRSA clinical isolates without 
previous molecular characterization, 29 (72.5%) 
were classified as CA-MRSA and 11 (27.5%) 
M NC1 U CH NC2 U CH U CH NC3 MW
500 bp
200 bp
100 bp
arcC gmk
Hinf\ Cai\ Hha\
Figure 1. DNA fragments obtained after 
the amplification and restriction of the 
arcC and gmk genes for the USA300 
clone (U) (ST8) and the Chilean clone 
(CH) (ST5). Lanes 3 and 4: restriction 
of the arcC gene with the HinfI enzyme. 
Lanes 6 and 7: restriction of the gene 
gmk with the CaiI enzyme. Lanes 8 
and 9: restriction of the gmk gene 
with the HhaI enzyme. MW: Molecular 
weight of 50 bp. NC1, NC2 and NC3: 
respective negative controls of the 
three restriction reactions. 
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Figure 2. Multiple PCR of the 
lukF-PV/lukS-PV, sek, bsaB, 
sem and seo, genes amplified 
in the USA300 clone (U), 
Chilean clone CH93 (CH) and 
the clinical isolates 5sau23, 
5sau46, 5sau78 and 5sau80 
(Lanes 5 and 8). MW: Molecular 
weight of 100 bp. NC: negative 
control.
500 bp lukF/\ukS-PV
MW U CH NC 5 6 7 8
seo
sek
sem
bsaB300 bp
100 bp
Table 1. Primers used in this study
Primer Sequence (5’ to 3’) product (bp) Target gene Reference
GP287 ATCATTAGGTAAAATGTCTGGACATGAT 433 lukF-PV
   /lukS-PV (20)
GP286 GCATCAACTGTATTGGATAGCAAAAGC
GP265 GTGTCTCTAATAGTGCCAGC 596 seK (9)
GP264 ACTTTTTTGGTAACCCATCATC
GP336 TTGGATTTGGCGAGGAATTA 296 bsaB This study
GP337 AATTGTTGTCCCGAAACCTG
GP259 CGGTGGAGTTACATTAGCAGGT 376 sem (9,20)
GP258 TTCAGTTTCGACAGTTTTGTTGT
GP255 AGTTTGTGTAAGAAGTCAAGTGTA 180 seo (20)
GP254 ATCTTTAAATTCAGCAGATATTCCATC
GP223 TCACCAGCGCGTATTGTCAT 332 arcC  This study
GP222 AAGACTGAGTCTGGCTGTTC
GP225 CAGGACCATCTGGAGTAGGT 557 gmk  This study
GP224 CTTAGCTTCTACGCGCTCTC
Table 2. Nucleotide variations found in the six alleles of the six housekeeping genes used for MLST in S. aureus. The ST5 alleles 
are used as a reference to indicate where the nucleotide changes position. 
Gene Protein Allele  (ST) Nucleotide variations*
arcC Carbamate kinase 1 (ST5) ------- 
  2 (ST8) C198T,A199G,C210T
aroC Shikimate dehydrogenase 4 (ST5) ------- 
  3 (ST8) T102A, G435A
gmk Guanylate Kinase 4 (ST5) ------- 
  1 (ST8) T129C, T286C,T318A, 
   C357T,A358G
Pta Phosphate acetyltransferase 12 (ST5) ------- 
  4 (ST8) A294C
tpi Triosephosphate isomerase 1 (ST5) ------- 
  4 (ST8) T69A,G195A
yqil Acetyl coenzyme A acetyltransferase 10 (ST5) ------- 
  3 (ST8) A192G,G303A,C333T,T495A
*The ST5 alleles are used as a reference to indicate where the nucleotide changes position.
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were classified as HA-MRSA using the two 
methods. With the first method, the 29 CA-MRSA 
isolates evaluated showed a restriction profile of 
the genes arcC and gmk expected of CA-MRSA 
isolates, the 11 HA-MRSA isolates analyzed showed 
restriction profiles that were characteristic of HA-
MRSA isolates (100% exactitude). With the second 
method, the 29 CA-MRSA isolates amplified at least 
one of the sek, bsaB or lukF-PV/lukS-PV genes 
and all HA-MRSA isolates amplified the sem and 
seo genes. The subsequent molecular and genetic 
characterization showed that all isolates classified 
CA-MRSA were related to USA300 clone and 
all isolates classified HA-MRSA were related to 
Chilean clone. These results confirm that the two 
methods correctly identified both the CA-MRSA and 
HA-MRSA isolates (100% exactitude) (table 3).
Discussion
Several international studies have demonstrated 
that the CA-MRSA isolates are more virulent than 
the HA-MRSA isolates, due to greater production 
of virulence factors such as the Panton-Valentine 
leukocidin (PVL) and the phenol-soluble modulins 
(PSM), capable of lysing macrophages and 
neutrophils (5,6). Additionally, the CA-MRSA 
isolates contains genetic mobile elements that 
give them greater environmental adaptability--
as is the case with the arginine catabolic mobile 
element (ACME), specifically identified in the 
USA300 clone (21). Clinically, the CA-MRSA 
isolates have acquired the capacity not only to 
cause minor infections in healthy persons, but also 
to cause severe infections such as pneumonia and 
necrotizing fasciitis (16). The entry of CA-MRSA 
to hospitals and their greater virulence indicates 
an expected increase in patient  mortality and 
morbidity in affected institutions. This underlines 
the importance of developing methods that allow 
rapid identification of CA-MRSAs, and hence, more 
effective treatment, control and eradication of these 
infections.
Currently, the CA-MRSA and HA-MRSA isolates are 
differentiated with greater accuracy using robust 
and expensive techniques like PFGE and MLST. 
In developing countries such as Colombia and 
others in the Andean region, faster and cheaper 
alternative methods are necessary to differentiate 
between these types of microorganisms in 
hospitals. Herein,methods have been standardized 
for the rapid identification of Colombian CA-
MRSA isolates; the methods were designed based 
on isolates from several multi-centre studies 
(with epidemiological data as well as molecular 
and genetic characterizations), as well as new 
isolates without molecular characteristics and later 
confirmed by PFGE and MLST (4,9,10,22,23).
The first method was based on the detection of 
polymorphism, by means of restriction enzymes, 
found in two constitutive genes of S. aureus, which 
are used in MLST. This method correctly identified 
the 153 CA-MRSA isolates (100%) and 41 of the 
44 HA-MRSA isolates  (93.2%). A more detailed 
analysis of the molecular characteristics of the 
three HA-MRSA isolates classified as CA-MRSA 
was conducted. This revealed that these have a 
SCCmec III and a PFGE pulsotype (named as H, 
Table 3. Classification of the 237 MRSA clinical isolates by means of the two standardized methods.
                                                                                                                Possible ST according to 
                        the first method
Type of Isolate* PFGE   (n) SCCmec   PVL  HinfI HhaI CaiI Type of isolate Type of isolate
 pulsotype**   type    n (% )    -  first method -  second method
Isolates with previous molecular and genetics characterization (n=197)
CA-MRSA U (153) Type IVc 149 (97%) 8 8 8 CA-MRSA CA-MRSA
HA-MRSA F (32) Type I 0 (0%) 5 5 5 HA-MRSA HA-MRSA
 D (4) Type IV 0 (0%) 5 5 5 HA-MRSA HA-MRSA
 G (4) Type II 0 (0%) 5 5 5 HA-MRSA HA-MRSA
 H (3) Type III 0 (0%) 8 NC*** 8 CA-MRSA HA-MRSA
 R (1) Type II 0 (0%) 5 5 5 HA-MRSA HA-MRSA
Isolates without previous molecular and genetics characterization (n=40)
CA-MRSA U (29) Type IVc 24 (100%) 8 8 8 CA-MRSA CA-MRSA
  Type IVa 4 (100%) 8 8 8 CA-MRSA CA-MRSA
  Type IVb 1 (100%) 8 8 8 CA-MRSA CA-MRSA
HA-MRSA F (11) Type I 0 (0%) 5 5 5 HA-MRSA HA-MRSA
*Classified by molecular techniques such as PFGE, MLST and / or spa typing.
**Two isolates belong to different pulsotypes when they present >6 bands of difference in their restriction profile. 
***NC: No restriction enzyme cuts.
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table 3) possibly related to the Brazilian clone. This 
clone possesses a SCCmec IIIa and an ST239. Its 
allelic combination is 2-3-1-1-4-4-3, a single locus 
variant (SLV) from ST8 (3-3-1-1-4-4-3); allele 2 of 
the arcC gene also possesses the mutation C198T, 
as found in ST8. For this reason,the restriction 
enzyme HinfI did not cut the arcC gene in the 
three isolates, and consequently classified as CA-
MRSA. The epidemiological data indicated that 
the circulation of isolates related to the Brazilian 
clone is very low, with a frequency of less than 
1% (unpublished data). The first method correctly 
identified all of the “new” 29 CA-MRSA isolates and 
11 HA-MRSA isolates (100%). 
Various methods have been developed to try to 
identify CA-MRSA isolates at an international level 
(24,25). For example, Diep et al. (2003) reported 
a method that established the genetic relationship 
between two or more isolates from S. aureus by 
analyzing the polymorphism of amplified fragments 
of the 7 genes used for MLST, utilizing restriction 
enzymes (26). Unfortunately, this method does not 
allow the easy differentiation between ST5 and 
ST8 isolates--it generates DNA fragments with very 
similar size because it uses the primers employed 
by the MLST.
The second method correctly identified the 197 
CA-MRSA and HA-MRSA isolates, including the 3 
HA-MRSA isolates possibly related to the Brazilian 
clone. This method allowed the differentiation 
between the Colombian CA-MRSA and HA-MRSA 
isolates by the detection of specific virulence 
factors for each type of isolate. The fundamental 
characteristic of these virulence factors are their 
location on mobile genetic elements, which are 
acquired differently in the two types of isolates. The 
sek, bsaB, lukF-PV/lukS-PV genes were selected 
using results previously obtained by the current 
study and as reported in other literature (9,10), and 
the selection supported by a bioinformatics analysis 
of their location on the genome. In accordance with 
the genome sequence of the USA300 clone (21), 
the sek, bsaB, lukF-PV/lukS-PV genes are found 
on different mobile genetic elements. The first is 
transported on the pathogenicity island 5 (SaPI5), 
the second on the genomic island β (vSaβ) type 
II and the third on the prophage Sa2usa. The 
selection of specific virulence factors for the HA-
MRSA isolates was made using information from 
studies previously carried out in our laboratory 
(the genomes of the Chilean/Cordóbes and 
Pediatric clones have not yet been sequenced). 
These studies verified that approximately 90% of 
the HA-MRSA isolates contained the egc cluster 
(9). This cluster has been found on the genomic 
island β (vSaβ) type I of the strains N315, Mu50 
and Mu3 (27). Fossum et al. (2009) analyzed 821 
MRSA isolates and found that each genetic lineage 
possessed a specific repertoire of enterotoxins. 
This supports the hypothesis that mobile genetic 
elements are not inserted in all isolates and are 
not randomly distributed (28). Miranda et al. (2007) 
reported the emergence of isolates that were 
genetically related to the USA800 clone (ST5-
SCCmec IV) in Brazil. These were related to the 
Pediatric clone, with all of the isolates carrying 
the egc enterotoxin cluster. These observations 
confirmed that the cluster is widely disseminated 
in isolates related to the Pediatric clone, not only 
in Colombia, but also in neighboring countries 
(29). The second method identified correctly both 
the CA-MRSA and HA-MRSA isolates (100%), as 
well as CA-MRSA and HA-MRSA isolates without 
previous molecular characterization (100%). These 
results indicate that the two methods may be used 
for a correct determination a MRSA isolate may be 
either a CA-MRSA or HA-MRSA isolate.
The two methods standardized in this study allow 
the identification of the CA-MRSA isolates in a short 
period of time (approximately 5 hours) and with a 
lower cost compared to techniques such as PFGE 
and MLST. Furthermore, even if these methods 
were based on Colombian CA-MRSA isolates, they 
have the potential to identify CA-MRSA isolates 
in the for the entire Andean region (Colombia, 
Venezuela, Ecuador and Peru), given that the 
epidemiology of these countries is similar to that 
of Colombia.  The pulsotypes obtained from PFGE 
show that the majority of the HA-MRSA isolates 
have a close genetic relation to the Chilean clone; 
and the CA-MRSA isolates, as in Colombia, are 
genetically related to the USA300 clone (10,30). 
These determinations will be of value even if 
additional studies are required to confirm the STs 
and whether the STs possess these same specific 
virulence factors. 
The development of these diagnostic tools is an 
important advance that allows faster and more 
accurate identifications of the MRSA isolate. Rapid 
identifications will in turn quickly orientate the 
medical staff toward a more appropriate empirical 
antibiotic treatment and assist an adequate 
therapeutic management of CA-MRSA infections. 
Finally, without the of knowledge of the genetic 
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and molecular characteristics of the isolates, 
inappropriate treatments can result in increased 
resistance of bacterial agents to antibiotics, 
and, once established, reduces the therapeutic 
possibilities for treatment. 
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